

HIV TREATMENT

APPROACHES TO ENHANCE AND ACCELERATE STUDY OF NEW DRUGS FOR HIV AND ASSOCIATED INFECTIONS IN PREGNANT WOMEN

DECEMBER 2021





.

HIV TREATMENT

MEETING REPORT

APPROACHES TO ENHANCE AND ACCELERATE STUDY OF NEW DRUGS FOR HIV AND ASSOCIATED INFECTIONS IN PREGNANT WOMEN

DECEMBER 2021





Approaches to enhance and accelerate study of new drugs for HIV and associated infections in pregnant women: meeting report

ISBN 978-92-4-004018-2 (electronic version) ISBN 978-92-4-004019-9 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

Suggested citation. Approaches to enhance and accelerate study of new drugs for HIV and associated infections in pregnant women: meeting report. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/copyright.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

CONTENTS

BACKGROUND	1
OBJECTIVES.	1
METHODS	2
SUMMARY AND KEY OUTCOMES	
CONCLUSION AND NEXT STEPS	7
ANNEX 1. LIST OF PARTICIPANTS	8
ANNEX 2. WORKSHOP PART 1 – AGENDA	10
ANNEX 3. WORKSHOP PART 2 – AGENDA	



The WHO and the IMPAACT Network facilitated a workshop, Approaches to Enhance and Accelerate Study of New Drugs for HIV and Associated Infections in Pregnant Women, aimed at gaining consensus on the optimal timing and design of studies of new drugs for treating and preventing HIV and related conditions among pregnant women. This workshop brought together women living with HIV, academic researchers, clinical experts, regulators, industry leaders, funders and other key stakeholders involved in studying HIV-related drugs for pregnant women. The workshop was held virtually on 8-10 December 2020 (part 1) and 6-7 July 2021 (part 2).

BACKGROUND

With more than 19 million women living with HIV worldwide – most of whom are of childbearing potential – there is a public health imperative to ensure that they can make informed choices about the drugs they take for HIV treatment or prevention. Information to support optimal antiretroviral drug choices in pregnancy has rarely been available for women or their health-care providers, largely because of historically protectionist and conservative approaches to clinical studies conducted among pregnant and breastfeeding women.

Pregnant and breastfeeding women are usually excluded from clinical trials of new agents (pre- and post-licensure). In addition, women of childbearing potential are typically underrepresented in pre-licensure drug trials and are usually required to use dual contraception to participate. Further, those who become pregnant while participating must discontinue the study drug. Therefore, pregnancy safety and pharmacokinetic data for new drugs are routinely delayed by as much as a decade after initial drug approval if studies are performed at all. This results in substantial delays in women accessing new and better drugs. Additionally, despite the lack of data, these new drugs are prescribed for women of childbearing potential who become pregnant as well as for pregnant women. This results in women having to make decisions about using new agents without adequate information about dosing or safety in pregnancy. This lack of information from trials to guide pregnant women in using antiretroviral drugs shifts the burden of potential risk around drug safety from the clinical trial setting in which safety outcomes are carefully monitored to the real-world clinical care setting in which safety outcomes are not systematically captured.

Multiple agencies and actors have voiced their concerns around the exclusion of pregnant women from clinical trials and the associated harm and risks of these policies. More recently, the importance of allowing pregnant women the opportunity to take part in clinical trials has received renewed attention during the COVID-19 pandemic. Recognizing the urgency of addressing this issue, the IMPAACT Network and WHO held a workshop to refine optimal approaches to studying the safety and efficacy of new HIV-related drugs during pregnancy and to establish the next steps for creating materials and methods that would support the implementation of such studies.

OBJECTIVES


The overall objectives of the workshop were:

- to refine key principles around optimal approaches to studying new drugs for HIV (treatment or prevention) and associated infections in pregnant women: develop a framework for setting priorities, accelerating and optimizing the type and timing of studies involving pregnant women;
- to review and refine best practices on how to include pregnant women in studies of new drugs that are in Phase 3 studies for non-pregnant individuals; and
- to formulate a strategic action plan for promoting the inclusion of pregnant women in research on new HIV treatment and prevention drugs before drug regulatory authorization.

METHODS

The workshop co-convened by WHO and the IMPAACT Network brought together more than 100 participants from across the world, including women living with HIV, academic researchers, clinical experts, regulators, industry representatives, funders and other key stakeholders involved in studying drugs for the prevention and treatment of HIV and other infectious diseases among pregnant women. Organizations represented included WHO, IMPAACT, University of Geneva, HIV i-Base, Paediatric Antiretroviral Working Group, PANGEA, International AIDS Society, pharmaceutical companies involved in developing HIV agents, United States Food and Drug Administration, European Medicines Agency, Special Programme for Research & Training in Tropical Diseases, National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Elizabeth Glaser Pediatric AIDS Foundation, Imperial College London, United States Agency for International Development, AIDS Clinical Trials Group, Microbicide Trials Network, Unitaid, HIV Prevention Trials Network, PHPT, Pregnancy and HIV/ AIDS: Seeking Equitable Study, AfroCAB, Treatment Action Campaign, The Lancet, EUROmediCAT, RTI International, Medicines for Malaria Venture and many more including various academic institutions.

Fig.1 Outline of the workshop



预览已结束, 完整报告链接和二维码如下:



2

https://www.yunbaogao.cn/report/index/report?reportId=5_23481